# Clinical Endpoint Study of Ivermectin 1% Cream

> **NCT02840461** · PHASE3 · COMPLETED · sponsor: **Actavis Inc.** · enrollment: 630 (actual)

## Conditions studied

- Moderate to Severe Papulopustular Rosacea

## Interventions

- **DRUG:** Ivermectin Cream, 1%
- **DRUG:** Placebo/Vehicle cream

## Key facts

- **NCT ID:** NCT02840461
- **Lead sponsor:** Actavis Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2016-11
- **Final completion:** 2016-12
- **Target enrollment:** 630 (ACTUAL)
- **Last updated:** 2020-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02840461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02840461, "Clinical Endpoint Study of Ivermectin 1% Cream". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02840461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*